By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG 

Brunner Strasse 69, Obj.3

Vienna    1230  Austria
Phone: 43-1-902-50 Fax: 43-1-902-50-901



Company News
DVC Deutsche Venture Capital Achieves Further Successful Transactions And Exits Within Its Life Sciences Portfolio In The 1st Quarter 200510/19/2005 5:13:15 PM
Aphton Corporation (APHT) Announces Closing Of Igeneon Acquisition10/19/2005 5:13:07 PM
Aphton Corporation (APHT) Shareholders Approve Acquisition Of Igeneon10/19/2005 5:13:05 PM
Aphton Corporation (APHT) To Acquire Igeneon Extending Its Leadership Position In Cancer Immunotherapy; Acquisition Represents Pivotal Step To Establishing A Broad Oncology Franchise10/19/2005 5:12:28 PM
Aphton Corporation (APHT) And VaxGen, Inc.'s (VXGN) Joint Venture Celltrion, Inc. Announce Commercialization And Manufacturing Agreements For IGN311 With Igeneon10/19/2005 5:12:08 PM
Igeneon Initiates Further Pivotal Phase III Clinical Trials With IGN101 Cancer Vaccine10/19/2005 5:10:31 PM
Oncology-Focused Igeneon Raises EUR26.7M, Ponders IPO10/19/2005 5:10:16 PM
Igeneon Raises EUR 26.7 Million (US$34.3 million) In A Series C Financing Round Co-Led By Burrill & Company And 3i10/19/2005 5:10:11 PM
Aphton Corporation (APHT) Reports Activity Of IGN101 In Reducing Disseminating Tumor Cells From Patients With Epithelial Cancers10/19/2005 5:10:07 PM
Igeneon Expands Management Board In 200410/19/2005 5:09:38 PM